Key Data Updates and Treatment Trends in Ovarian Cancer From ASCO 2025 - Episode 4

Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: The ROSELLA Trial

,

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

EP. 1: Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management
EP. 2: Data for First-Line Dostarlimab and Niraparib in Advanced Ovarian Cancer: The FIRST Trial
EP. 3: TRUST Trial: Outcomes With Radical Up-Front Surgery in Advanced Ovarian Cancer
Now Viewing
EP. 4: Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: The ROSELLA Trial
EP. 5: Findings for Neoadjuvant IMNN-001 Plus Chemo in Newly Diagnosed, Advanced Epithelial Ovarian Cancer
EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025 and Beyond

Related Content:

Key Data Updates and Treatment Trends in Ovarian Cancer From ASCO 2025Dana-Farber Cancer InstituteUCLA Health Jonsson Comprehensive Cancer CenterOncLive News Network®
Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC
Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
Dr Tolaney on the Design of the ELEGANT Trial in ER+, HER2-Negative Early Breast Cancer